A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in wh...

Full description

Bibliographic Details
Main Authors:	Ol'ga Veniaminovna Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva, O V Stakhina
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2010-02-01
Series:	Терапевтический архив
Subjects:	chronic myeloid leukemia drug-induced pneumonitis interstitial pneumonia imatinib mesylate
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/30558

Similar Items

Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection
by: Zhuan - Bo Luo, et al.
Published: (2017-11-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2021-01-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia
by: Ahmet Emre Eşkazan, et al.
Published: (2013-12-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

Histological changes of the rat liver after administration of imatinib mesylate:an experimental study
by: Luma Ibrahim Khalel Al-Allaf, et al.
Published: (2019-06-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

THE EFFECT OF IMATINIB MESYLATE IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC-PHASE MYELOID LEUKEMIA IN SUB-SAHARAN AFRICAN PATIENTS: THE EXPERIENCE OF CÔTE D’IVOIRE
by: GUSTAVE Kouassi KOFFI, et al.
Published: (2014-08-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi
by: Anil Babar, et al.
Published: (2024-04-01)

Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
by: Shreya Agrawal, et al.
Published: (2023-01-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Acompanhamento farmacoterapêutico dos pacientes com leucemia mieloide crônica em uso de mesilato de imatinibe na Universidade Federal do Ceará The pharmacotherapeutic follow- up of patients with chronic myeloid leukemia (CML) on imatinib mesylate therapy
by: Sterfen S. Aquino, et al.
Published: (2009-01-01)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Marjanu Hikmah Elias, et al.
Published: (2012-11-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate
by: Ikhwan Rinaldi, et al.
Published: (2020-09-01)

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate
by: Ismail Siti Mariam, et al.
Published: (2022-08-01)

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis
by: Megan E. Perkins, et al.
Published: (2022-05-01)

A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate
by: E. B. Myakoshina, et al.
Published: (2020-09-01)

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
by: Caterina Musolino, et al.
Published: (2015-05-01)

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate
by: Kritamorn Jitrangsri, et al.
Published: (2023-09-01)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01)

Subclinical Hypothyroidism Following Imatinib Use in Nigerian BCR::ABL1-positive Chronic Myeloid Leukemia Patients: A Prospective Cohort Study
by: Ibrahim Oluwaseun Ahmed, et al.
Published: (2024-09-01)

Nail lichen planus associated with imatinib mesylate
by: Eden Axler, BS, et al.
Published: (2025-04-01)

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
by: Xiuyan Zhang, et al.
Published: (2023-10-01)

Optimization Studies on Imatinib Mesylate Loaded Nanoliposomes Using Box-Behnken Design
by: Mandeep Dahiya, et al.
Published: (2022-03-01)

Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series
by: Deborah van de Wal, et al.
Published: (2024-03-01)

Aplasia irreversible por el tratamiento con mesilato de Imatinib en una leucemia mieloide crónica: Presentación de un caso Irreversible aplasia due to the treatment with imatinib mesilate in a chronic myeloid leukemia: A case report
by: Olga Agramonte Llanes, et al.
Published: (2007-04-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019-07-01)

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
by: Asiyeh Amouei, et al.
Published: (2021-04-01)